Status:
UNKNOWN
Aldosterone in Diabetic Nephropathy
Lead Sponsor:
Universidad de los Andes, Chile
Conditions:
Diabetic Nephropathy
Eligibility:
All Genders
30-70 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine whether spironolactone are effective in the reduction of albuminuria and diastolic disfunction of subjects with diabetic nephropathy.
Eligibility Criteria
Inclusion
- Diabetic subjects with maximum ten years after diagnostic
- Diabetic nephropathy with albuminuria
- Normal renal function
- Diastolic disfunction
- Taking a IECA or ARA drug family previously
Exclusion
- Diabetics subjects with macroangiopathy
- Acute coronary syndrome in the three months before
- Hyperkalemia \> 5.5 mEq/L
- Pregnancy
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2010
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT00870402
Start Date
March 1 2009
End Date
March 1 2010
Last Update
March 27 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Los Andes
Santiago, Santiago Metropolitan, Chile, 762000